natgillin/translations-raw huggingface dataset:
In the DTC study (see Lenvima SmPC), QT/QTc interval prolongation was reported in 8.8% of lenvatinib- treated patients and 1.5% of patients in the placebo group.
U ispitivanju diferenciranog karcinoma štitnjače (vidjeti Sažetak opisa svojstava lijeka za Lenvimu), produljenje QT/QTc intervala zabilježeno je u 8,8% bolesnika liječenih lenvatinibom i 1,5% bolesnika iz skupine koja je primala placebo.
In the Dupuytren’s contracture clinical trials at 30 days post the first injection, 92% of patients had circulating antibodies detected against AUX-I and 86% of patients against AUX-II.
U kliničkim ispitivanjima u Dupuytrenovoj kontrakturi trideset dana nakon prve injekcije, u 92% bolesnika otkrivena su cirkulirajuća protutijela na AUX-I, a u 86% bolesnika na AUX-II.
In the early post-transplant period (< 40 days post-transplant), renal, cardiac and hepatic transplant patients had mean MPA AUCs approximately 30% lower and Cmax approximately 40% lower compared to the late post-transplant period (3 – 6 months post-transplant).
U ranom razdoblju nakon presađivanja (< 40 dana nakon presađivanja) srednja vrijednost AUC-a MPA kod bolesnika s presađenim bubregom, srcem ili jetrom bila je otprilike 30% niža, dok je Cmax bio otprilike 40% niži u odnosu na kasnije razdoblje nakon presađivanja (3 - 6 mjeseci nakon presađivanja).
In the early post-transplant period (< 40 days post-transplant), renal, cardiac and hepatic transplant patients had mean MPA AUCs approximately 30% lower and Cmax approximately 40% lower compared to the late post-transplant period (3 – 6 months post-transplant).
U ranom razdoblju nakon presađivanja (< 40 dana nakon presađivanja), srednja vrijednost AUC-a MPA kod bolesnika s presađenim bubregom, srcem ili jetrom bila je otprilike 30% niža, dok je Cmax bio otprilike 40% niži u odnosu na kasnije razdoblje nakon presađivanja (3 - 6 mjeseci nakon presađivanja).
In the early post-transplant period (<°40 days post-transplant), renal, cardiac and hepatic transplant patients had mean MPA AUCs approximately 30% lower and Cmax approximately 40% lower compared to the late post-transplant period (3 - 6°months post-transplant).
U ranom razdoblju nakon presađivanja (< 40 dana nakon presađivanja), srednji AUC MPA kod bolesnika s presađenim bubregom, srcem ili jetrom bio je otprilike 30% niži, dok je Cmax bio otprilike 40% niži u odnosu na kasnije razdoblje nakon presađivanja (3 – 6 mjeseci nakon presađivanja).
In the early post-transplant period (<°40 days post-transplant), renal, cardiac and hepatic transplant patients had mean MPA AUCs approximately 30% lower and Cmax approximately 40% lower compared to the late post-transplant period (3 – 6°months post-transplant).
U ranom razdoblju nakon presađivanja (< 40 dana nakon presađivanja), srednji AUC MPA kod bolesnika s presađenim bubregom, srcem ili jetrom bio je otprilike 30% niži, dok je Cmax bio otprilike 40% niži u odnosu na kasnije razdoblje nakon presađivanja (3 - 6 mjeseci nakon presađivanja).
In the echocardiography studies, SonoVue was more effective than the comparator and than placebo in improving the clarity of the image obtained of the left ventricle and left ventricle border.
U ispitivanjima ehokardiografije SonoVue je bio učinkovitiji od komparatora i od placeba u poboljšavanju bistrine dobivenih slika lijevog ventrikula i granice lijevog ventrikula.
In the efavirenz+emtricitabine/tenofovir disoproxil fumarate arm the mean change from baseline in total cholesterol (fasted) was 26 mg/dL, in
U skupini liječenoj efavirenz+emtricitabin/tenofovirdizoproksilfumarat srednja vrijednost promjene od početne vrijednosti kod ukupnog kolesterola (natašte) iznosila je 26 mg/dl, kod
In the Einstein DVT study (see Table 3) rivaroxaban was demonstrated to be non-inferior to enoxaparin/VKA for the primary efficacy outcome (p < 0.0001 (test for non-inferiority); hazard ratio: 0.680 (0.443 - 1.042), p=0.076 (test for superiority)).
U ispitivanju Einstein DVT (vidjeti tablicu 3) pokazano je da je rivaroksaban neinferioran u odnosu na enoksaparin/antagonist vitamina K za primarni ishod djelotvornosti (p < 0,0001 (ispitivanje neinferiornosti); omjer hazarda: 0,680 (0,443 – 1,042), p=0,076 (ispitivanje superiornosti)).
In the Einstein DVT study (see Table 5) rivaroxaban was demonstrated to be non-inferior to enoxaparin/VKA for the primary efficacy outcome (p < 0.0001 (test for non-inferiority); hazard ratio: 0.680 (0.443 - 1.042), p=0.076 (test for superiority)).
U ispitivanju Einstein DVT (vidjeti tablicu 5) pokazano je da je rivaroksaban neinferioran u odnosu na enoksaparin/antagonist vitamina K za primarni ishod djelotvornosti (p < 0,0001 (ispitivanje neinferiornosti); omjer hazarda: 0,680 (0,443 – 1,042), p=0,076 (ispitivanje superiornosti)).
In the Einstein Extension study (see Table 6) rivaroxaban was superior to placebo for the primary and secondary efficacy outcomes.
U ispitivanju Einstein Extension (vidjeti tablicu 6) rivaroksaban je bio superioran placebu kod primarnih i sekundarnih ishoda djelotvornosti.
In the Einstein PE study (see Table 4) rivaroxaban was demonstrated to be non-inferior to enoxaparin/VKA for the primary efficacy outcome (p=0.0026 (test for non-inferiority); hazard ratio: 1.123 (0.749 – 1.684)).
U ispitivanju Einstein PE (vidjeti tablicu 4) pokazano je da rivaroksaban nije inferioran u odnosu na enoksaparin/ antagonist vitamina K za primarni ishod djelotvornosti (p= 0,0026 (ispitivanje neinferiornosti); omjer hazarda: 1,123 (0,749 – 1,684)).
In the Einstein PE study (see Table 6) rivaroxaban was demonstrated to be non-inferior to enoxaparin/VKA for the primary efficacy outcome (p=0.0026 (test for non-inferiority); hazard ratio: 1.123 (0.749 – 1.684)).
U ispitivanju Einstein PE (vidjeti tablicu 6) pokazano je da rivaroksaban nije inferioran u odnosu na enoksaparin/ antagonist vitamina K za primarni ishod djelotvornosti (p= 0,0026 (ispitivanje neinferiornosti); omjer hazarda: 1,123 (0,749 – 1,684)).
In the elderly frequencies were similar, except for myalgia, headache and injection site pain which were classified as ‘common’.
U starijih osoba učestalosti su bile slične, osim za mijalgiju, glavobolju i bol na mjestu injiciranja koje su klasificirane kao „česte”.
In the elderly population (≥ 65 years of age) 4 of 5 patients (80.0%) achieved CR/CRh* within 2 treatment cycles (see section 4.8 for safety in elderly).
U populaciji starijih bolesnika (u dobi od ≥ 65 godina), 4 od 5 bolesnika (80,0%) postiglo je CR/CRh* unutar dva ciklusa liječenja (vidjeti dio 4.8 za informacije o sigurnosti u starijih bolesnika).
In the elderly, the reported reactions increased with the third booster dose only when compared with the second dose.
U starijih osoba, prijavljen je povećan broj reakcija nakon treće booster doze samo u usporedbi s drugom dozom.
In the eligible population, the subgroup analyses according to the prior cisplatin use versus BSC on overall survival (OS) showed a HR (95% CI) = [0.64 (0.40 – 1.03); p=0.0821] in the absence of prior cisplatin, and a HR (95% CI) = [0.80 (0.60 – 1.06); p=0.1263] in the presence of prior cisplatin.
U populaciji koja je zadovoljila uključne kriterije, analiza ukupnog preživljenja (OS) u podskupinama bolesnika s prethodnom primjenom cisplatina i onih koji su primali BSC pokazala je omjer hazarda (HR) (95%-tni CI) = [0,64 (0,40 – 1,03); p=0,0821] bez prethodne primjene cisplatina i omjer hazarda (HR) (95%-tni CI) = [0,80 (0,60 – 1,06); p=0,1263] uz prethodnu primjenu cisplatina.
In the enoxaparin/VKA group, there was no clear relation between the level of mean centre TTR (Time in Target INR Range of 2.0 – 3.0) in the equally sized tertiles and the incidence of the recurrent VTE (p=0.082 for interaction).
U skupini s enoksaparinom/antagonistom vitamina K nije bilo jasnog odnosa između razine srednjeg centralnog vremena unutar terapijskog raspona (vrijeme u ciljnom INR rasponu od 2,0-3,0) u jednako velikim trećinama i incidencije ponavljajućeg VTE-a (P=0,082 za interakciju).
In the enoxaparin/VKA group, there was no clear relation between the level of mean centre TTR (Time in Target INR Range of 2.0 – 3.0) in the equally sized tertiles and the incidence of the recurrent VTE (P=0.932 for interaction).
U skupini s enoksaparinom/antagonistom vitamina K nije bilo jasnog odnosa između razine srednjeg centralnog vremena unutar terapijskog raspona (vrijeme u ciljnom INR rasponu od 2,0-3,0) u jednako velikim trećinama i incidencije ponavljajućeg VTE-a (P=0,932 za interakciju).
In the eptifibatide arm of the trial, virtually all patients received aspirin (99.7 %), and 98.1 % received a thienopyridine, (clopidogrel in 95.4 % and ticlopidine in 2.7 %).
U kraku ispitivanja koji je primao eptifibatid gotovo svi bolesnici primali su aspirin (99,7 %), a 98,1 % ih je primalo tienopiridin, (klopidogrel u 95,4 % i tiklopidin u 2,7 %).
In the ERT- naïve trial and open label extension, renal function remained stable for 3 years of treatment with Galafold.
U ispitivanju s bolesnicima koji nisu prethodno primali ERT, funkcija bubrega ostala je stabilna do 3 godine terapije lijekom Galafold.
In the ERT-experienced trial an analysis of a composite clinical outcome composed of renal, cardiac, and cerebrovascular events, or death, the frequency of events observed in the Galafold treatment group was 29% and was 44% in the ERT group.
U ispitivanju s bolesnicima koji su prethodno primali ERT, analiza kompozitnog kliničkog ishoda koji se sastojao od bubrežnih, srčanih i cerebrovaskularnih događaja ili smrti, je pokazala kako je učestalost događaja primijećenih u skupini koja je primala Galafold iznosila 29 %, a u skupini koja je primala ERT 44 %.
In the ERT-experienced trial, plasma lyso-Gb3 levels remained low and stable for up to 18 months in patients with amenable mutations switched from ERT to Galafold, and in patients remaining on ERT.
U ispitivanju s bolesnicima koji su prethodno primali ERT, razine lyso-Gb3 u plazmi ostale su niske i stabilne do 18 mjeseci u bolesnika s mutacijama koje omogućuju odgovor na liječenje koji su s ERT-a prešli na Galafold te u bolesnika koji su ostali primati ERT.
In the ERT-naïve trial, analyses of the Gastrointestinal Symptoms Rating Scale demonstrated that treatment with Galafold was associated with statistically significant (p<0.05) improvements versus placebo from baseline to month 6 in the diarrhoea domain, and in the reflux domain for patients with symptoms at baseline.
U ispitivanju s bolesnicima koji prethodno nisu primali ERT, analize ljestvice za ocjenu gastrointestinalnih simptoma pokazale su da je liječenje lijekom Galafold bilo povezano sa statistički značajnim (p < 0,05) poboljšanjima u odnosu na skupinu koja je primala placebo od početka ispitivanja do 6. mjeseca u području proljeva te refluksa za bolesnike koji su imali simptome na početku ispitivanja.
In the ERT-naïve trial, Galafold resulted in a statistically significant decrease in LVMi (p< 0.05); the mean change from baseline in LVMi at Month 18 to 24 was -7.7 (95% CI: -15.4, -0.01; n=27).
U ispitivanju s bolesnicima koji nisu prethodno primali ERT, Galafold je doveo do statistički značajnog smanjenja LVMi (p < 0,05); srednja vrijednost promjene u odnosu na početnu vrijednost LVMi od 18. do 24. mjeseca iznosila je –7,7 (95 % CI: -15,4; -0,01; n = 27).
In the EU study Osurnia was as effective as the comparator medicine with both treatments resulting in 63% reduction in severity of otitis externa.
U europskom ispitivanju Osurnia je bila jednako djelotvorna kao i usporedni lijek s obje terapije koje su rezultirale u 63-postotnoj redukciji težine otitisa externe.
In the European study, a total of 51 subjects with primary immunodeficiency syndromes aged between 3 and 60 years old were treated with Hizentra for up to 41 weeks.
U europskoj studiji, ukupno 51 ispitanika sa sindromom primarne imunodeficijencije u dobi između 3 i 60 godina bilo je liječeno Hizentrom do 41 tjedna.
In the evening, take 600 milligram PREZISTA together with 100 milligram ritonavir.
Navečer uzmite 600 miligrama lijeka PREZISTA zajedno sa 100 miligrama ritonavira.
In the evening, take one 200 milligram INTELENCE tablet, following a meal.
Navečer, nakon obroka uzmite jednu tabletu INTELENCEa od 200 miligrama.
In the evening, take one 600 milligram PREZISTA tablet together with 100 milligram ritonavir.
Navečer uzmite jednu tabletu lijeka PREZISTA od 600 miligrama zajedno sa 100 miligrama ritonavira.
In the evening, take two 100 milligram INTELENCE tablets, following a meal.
Navečer, nakon obroka uzmite dvije tablete INTELENCEa od 100 miligrama.
In the evening, take two 300 milligram PREZISTA tablets together with 100 milligram ritonavir.
Navečer uzmite dvije tablete lijeka PREZISTA od 300 miligrama zajedno sa 100 miligrama ritonavira.
In the event of a change in COPD intensity while the patient is being treated with aclidinium bromide so that the patient considers additional rescue medication is required, a re-evaluation of the patient and the patients’ treatment regimen should be conducted.
Ako za vrijeme liječenja aklidinijevim bromidom dođe do promjene intenziteta KOPB-a te bolesnik treba dodatni lijek za brzo ublažavanje simptoma, potrebno je ponovno procijeniti stanje bolesnika i način njegovog liječenja.
In the event of a hypoglycaemic episode, the infusion should be stopped until the episode is resolved.
Nastupi li hipoglikemija, infuziju treba prekinuti dok epizoda hipoglikemije ne prođe.
In the event of a medical emergency, you should tell your doctor, pharmacist or nurse that you have taken Sildenafil Teva and when you did.
U slučaju hitne medicinske intervencije, morate upozoriti svog liječnika, ljekarnika ili medicinsku sestru da ste uzeli Sildenafil Teva te kada ste ga uzeli.
In the event of a planned transfusion, the HCPs should notify blood transfusion centres about the interference with indirect antiglobulin tests;
U slučaju planirane transfuzije, potrebno je obavijestiti centre za transfuziju krvi o toj interferenciji s nalazima indirektnog antiglobulinskog testa;
In the event of a retinal break the dose should be withheld and treatment should not be resumed until the break is adequately repaired.
U slučaju pukotine mrežnice ne smije se primijeniti doza i ne smije se nastaviti s liječenjem sve dok se pukotina adekvatno ne zatvori.
In the event of a sensitisation or severe local irritation from the use of retapamulin ointment, treatment should be discontinued, the ointment carefully wiped off, and appropriate alternative therapy for the infection instituted.
U slučaju senzibilizacije ili teške lokalne iritacije zbog primjene retapamulin masti, potrebno je prekinuti liječenje, pažljivo obrisati mast te započeti s alternativnom terapijom infekcije.
In the event of a suspected overdose, the appropriate supportive clinical care should be instituted, as dictated by the subject’s clinical status.
U slučaju sumnje na predoziranje, treba uvesti odgovarajuće potporno kliničko liječenje u skladu s kliničkim statusom bolesnika.
in the event of accidental contact with the skin, exposed areas should be washed immediately with soap and water; in the event of accidental contact with the mucous membranes, exposed areas should be treated immediately by copious lavage with water; medical attention should be sought.
u slučaju nehotičnog kontakta s kožom, izloženo područje treba smjesta oprati sapunom i vodom. u slučaju nehotičnog kontakta sa sluznicama, izložena područja treba odmah obilno isprati vodom; treba potražiti medicinski savjet.
In the event of accidental contact, remove cream by rinsing with water.
Ako dođe do slučajnoga kontakta, uklonite kremu tako da je isperete vodom.
In the event of accidental oral ingestion of TOBI Podhaler capsules, toxicity is unlikely as tobramycin is poorly absorbed from an intact gastrointestinal tract.
U slučaju nenamjerne peroralne ingestije TOBI Podhaler kapsula, mala je vjerojatnost toksičnosti budući da se tobramicin slabo apsorbira iz intaktnog gastrointestinalnog trakta.
In the event of accidental overdose, a dose of calcium folinate equal to or higher than the offending dose of methotrexate should be administered intravenously or intramuscularly within 1 hour, and dosing continued until serum level of methotrexate are below 10-7 mol/L.
U slučaju nehotičnog predoziranja potrebno je u roku od 1 sata intravenski ili intramuskularno primijeniti dozu kalcijevog folinata jednaku ili višu od štetne doze metotreksata i nastaviti s doziranjem sve dok razina metotreksata ne bude niža od 10-7 mol/l.
In the event of administration of a radiation overdose with tilmanocept the absorbed dose to the patient should be reduced where possible by increasing the elimination of the radionuclide from the body by frequent micturition or by forced diuresis and frequent bladder voiding
U slučaju primjene prevelike doze zračenja pri primjeni tilmanocepta, dozu koju je bolesnik apsorbirao potrebno je, kad je to moguće, smanjiti ubrzavanjem eliminacije radionuklida iz tijela čestom mikturicijom ili prisilnom diurezom i čestim mokrenjem.
In the event of an abnormal blood count or liver function test finding, the clinical decision for continuing use or adjusting the dose of stiripentol in conjunction with adjusting the doses of clobazam and valproate needs to be made on an individual patient basis taking into consideration the potential clinical benefits and risks (see section 4.4).
U slučaju abnormalnosti u krvnoj slici ili jetrenim probama, za svakog bolesnika ponaosob mora se donijeti klinička odluka o nastavku primjene ili o podešavanju doze stiripentola, zajedno s podešavanjem doza kklobazama i valproata, uzimajući u obzir moguće kliničke prednosti ili moguće rizike (vidjeti dio 4.4).
In the event of an accidental occupational exposure to Imlygic (e.g. through a splash to the eyes or mucous membranes) during preparation or administration, flush with clean water for at least 15 minutes.
U slučaju slučajne profesionalne izloženosti lijeku Imlygic (npr. putem prskanja u oko ili na površinu sluznice) tijekom pripreme ili primjene, ispirati čistom vodom kroz najmanje 15 minuta.
In the event of an acute infusion reaction, the infusion rate may be decreased, or the infusion stopped, depending on the severity of the reaction.
U slučaju akutne infuzijske reakcije, moguće je smanjiti brzinu infuzije ili ju zaustaviti, ovisno o ozbiljnosti reakcije.
In the event of an anaphylactic reaction, beta blockers (including eye drop preparations) may aggravate the reaction.
U slučaju anafilaktičke reakcije, beta blokatori (uključuju pripravke kapi za oči) mogu pogoršati reakciju.
In the event of an injection site related adverse reaction occuring, appropriate measures to manage these events should be taken (see section 4.8).
U slučaju nastanka nuspojave na mjestu primjene injekcije moraju se poduzeti odgovarajuće mjere za njezino zbrinjavanje (vidjeti dio 4.8).
In the event of an officially declared influenza pandemic due to A/H5N1 virus, persons previously vaccinated with one or two doses of AFLUNOV that contained HaemAgglutinin (HA) antigen derived from a different clade of the same influenza subtype as the influenza pandemic strain may receive a single dose of AFLUNOV instead of two doses that are required in previously unvaccinated individuals (see section 5.1).
U slučaju službeno proglašene pandemije influence prouzročene virusom A/H5N1 osobe prethodno cijepljene s jednom ili dvije doze cjepiva AFLUNOV koje je sadržavalo antigen hemaglutinin (HA) dobiven iz različite linije istog podtipa influence kao pandemijski soj influence mogu primiti samo jednu dozu cjepiva AFLUNOV umjesto dviju doza koje su potrebne u prethodno necijepljenih pojedinaca (vidjeti dio 5.1).
In the event of an officially declared influenza pandemic due to A/H5N1 virus, persons previously vaccinated with one or two doses of Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics that contained HA antigen derived from a different clade of the same influenza subtype as the influenza pandemic strain may receive a single dose of Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics instead of two doses that are required in previously unvaccinated individuals (see section 5.1).
U slučaju službeno proglašene pandemije influence prouzročene virusom A/H5N1, osobe prethodno cijepljene s jednom ili dvije doze Prepandemijskog cjepiva protiv influence (H5N1) (površinski antigen, inaktivirano, adjuvantirano) Novartis Vaccines and Diagnostics koje je sadržavalo antigen HA dobiven iz različite linije istog podtipa influence kao pandemijski soj influence mogu primiti samo jednu dozu Prepandemijskog cjepiva protiv influence (H5N1) (površinski antigen, inaktivirano, adjuvantirano) Novartis Vaccines and Diagnostics umjesto dviju doza, koje su potrebne u prethodno necijepljenih pojedinaca (vidjeti dio 5.1).
In the event of an overdose of Vokanamet, it is reasonable to employ the usual supportive measures, e.g., remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring, and institute clinical measures as dictated by the patient’s clinical status.
U slučaju predoziranja lijekom Vokanamet, opravdano je primjeniti uobičajene potporne mjere, npr. ukloniti neapsorbirani lijek iz gastrointestinalnog trakta, vršiti klinički nadzor, te po potrebi uvesti kliničke mjere što ovisi o bolesnikovom kliničkom statusu.
In the event of an overdose with OLYSIO, it is recommended to employ the usual supportive measures and observe the patient’s clinical status.
U slučaju predoziranja lijekom OLYSIO, preporučuje se provesti uobičajene suportivne mjere i promatrati bolesnikov klinički status.
In the event of an overdose, appropriate supportive measures should be employed as dictated by the patient’s clinical status.
U slučaju predoziranja potrebno je poduzeti odgovarajuće potporne mjere koje odgovaraju kliničkom statusu bolesnika.
In the event of an overdose, appropriate supportive measures should be employed as dictated by the patient’s clinical status.
U slučaju predoziranja potrebno je poduzeti odgovarajuće potporne mjere koje određuje klinički status bolesnika.
In the event of an overdose, appropriate supportive treatment should be initiated as dictated by the patient’s clinical status.
U slučaju predoziranja potrebno je uvesti odgovarajuće potporno liječenje u skladu s kliničkim statusom bolesnika.
In the event of an overdose, appropriate supportive treatment should be initiated as dictated by the patient’s clinical status.
U slučaju predoziranja treba uvesti odgovarajuće potporno liječenje kako nalaže klinički status bolesnika.
In the event of an overdose, appropriate supportive treatment should be initiated as dictated by the patient’s clinical status.
U slučaju predoziranja treba uvesti odgovarajuće potporno liječenje u skladu s kliničkim statusom bolesnika.
In the event of an overdose, appropriate supportive treatment should be initiated as dictated by the patient’s clinical status.
U slučaju predoziranja, potrebno je započeti prikladne mjere liječenja u skladu sa bolesnikovim kliničkim statusom.
In the event of an overdose, physicians should follow general supportive measures and should treat symptomatically.
U slučaju predoziranja, liječnici se trebaju pridržavati općih suportivnih mjera i liječiti bolesnicu simptomatski.
In the event of an overdose, the patient’s vital signs should be monitored and appropriate supportive care given to maintain blood pressure (such as fluids, pressors, and/or inotropic agents) and body temperature (see sections 4.2 and 4.4).
U slučaju predoziranja potrebno je pratiti vitalne znakove bolesnika te im pružiti odgovarajuće potporne mjere za održavanje krvnog tlaka (kao što je tekućina, presorni lijekovi i/ili inotropni lijekovi) i tjelesne temperature (vidjeti dijelove 4.2 i 4.4).
In the event of an overdose, the patient’s vital signs should be monitored and appropriate supportive care given to maintain blood pressure and respiratory status.
U slučaju predoziranja potrebno je pratiti vitalne znakove bolesnika te poduzeti odgovarajuće potporne mjere kako bi se stabilizirali krvni tlak i disanje.